Navigation Links
NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sector's Recent Market Decline
Date:12/16/2013

n tumor.  This provides assurance that the antigen targets, which DCVax mobilizes the patient's immune system to hit, are actually on that patient's version of the cancer.  In contrast, the six antigens used in the Competitor's technology are pre-selected standardized antigens that may or may not be expressed, in whole or in part, on a given patient's version of GBM brain cancer.  The scientific literature has established that GBM is highly variable from patient to patient.

Experience Differences.  NW Bio's DCVax platform technology has been applied in two prior Phase I/II clinical trials for GBM, a small Phase I trial in metastatic ovarian cancer, a Phase I/II trial in late stage prostate cancer, a large number (over 100) prostate cancer patients in an academic setting, and a number of diverse compassionate use cases, over the course of more than ten years of clinical development.  The Competitor's technology had only previously been applied in one Phase I trial with 16 patients.

Clinical Trial Differences.  NW Bio is well under way with a 312-patient Phase III clinical trial.  The trial has been approved by three separate, highly rigorous regulators:  in the US, UK and Germany.  The DCVax technology and the Phase III trial have been evaluated by the National Health System (NIHR) in the UK and "adopted" as a nationwide priority in the UK.  NW Bio's Phase III trial is robustly designed.  If the primary endpoint is met, it is anticipated that this may result in a p value of 0.01 one-sided (0.02 two-sided), with a power of 82%.  A two-sided p value of 0.02 is well below (and hence stronger than) the p value of 0.05 which is generally needed for statistical significance.  Such a p value would provide a substantial cushion in case the difference in PFS turns out to be less than was projected in determining the statistical powering in the design of the trial. 
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Icahn Responds To Forest Labs Board
2. iMD Companies responds to shareholder questions
3. Concord Medical Responds to Unusual Market Activity in its Stock
4. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
5. Medbox Responds to Unprecedented Rise in Stock Price
6. TorkLaw Responds to FDA Warning Letter to St. Jude Medical Regarding Defective Heart Device; Now Representing Patients in 15 States
7. Star Scientific Responds to Plaintiffs Purported Class Action Lawsuit
8. Takeda Responds to Verdict in Diabetes Drug Case
9. National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill
10. Royalty Pharma Responds To Elans Tysabri Valuation
11. Inovio Pharmaceuticals Responds to Market Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ... composition, including reductions in body fat content and ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support ... heart failure, today announced that it expects revenues ... approximately $53 million, bringing expected full-year 2013 revenues ... revenue growth of 87% for 2013 above 2012 ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... event for buyers and sellers of high-value chemistry, will ... conference at the Miami Beach ... http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) More than 3,500 attendees ... will take part in the conference, which includes on-site ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Echo Therapeutics, Inc. (Nasdaq: ECTE ), ... non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and ... results for the third quarter and nine months ended ... is available through Echo,s website at www.echotx.com . ...
... Fla., Nov. 8, 2011 VR Laboratories LLC ... as chief scientific advisor.  Rothman will head scientific ... manufacture and bring to market world-class botanical consumer, ... foreign and domestic markets. In addition to assisting ...
Cached Medicine Technology:Echo Therapeutics Announces Third Quarter 2011 Financial Results 2Echo Therapeutics Announces Third Quarter 2011 Financial Results 3Echo Therapeutics Announces Third Quarter 2011 Financial Results 4Echo Therapeutics Announces Third Quarter 2011 Financial Results 5James Rothman Named Chief Scientific Advisor at VR Laboratories 2James Rothman Named Chief Scientific Advisor at VR Laboratories 3James Rothman Named Chief Scientific Advisor at VR Laboratories 4
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... says that workers with health insurance cover return to work ... said that research // conducted for it ... by workers returning early from illnesses. ,The current ... needed an operation and 76 uninsured workers. It was found ...
... press that it has completed the vaccination for all the ... // poultry were vaccinated across Vietnam. , ... the Ministry of Agriculture and Rural Development. ,Some ... whereas others received a booster dose for prevention of the ...
... comes a new study that links breakdown of myelin ... of California, Los Angeles (UCLA) researchers showed that genetic ... breakdown, may prove useful in assessing treatments for prevention ... a process uniquely built up in humans, arguably is ...
... Health Minister was issued notice after a complaint that said ... transfers // and appointments for medical and Para ... Justice K Sreedharan and Upa Lok Ayukta N Krishnan Nair ... others. ,Kerala Government Medical Officers Association (KGMOA) has ...
... medicine was safer than western alternatives // has ... watchdog said on Wednesday. ,The leaflet could dissuade ... serious medical conditions, the Advertising Standards Authority (ASA) said. ... claimed that serious medical problems such as cancer could ...
... ENT and Plastic Surgeon Dr. P. Thulasi Das and his ... Fluid (CSF) // leak to a 25 ... The patient was suffering from meningitis. Meningitis is the inflammation ... meningitis is caused by bacterial or fungal infections. Cerebrospinal fluid ...
Cached Medicine News:Health News:Chinese medicine leaflet broke advertising code 2
... Iodine 'Prep' solutions are ... mucous membrane preparation prior ... Povidone Iodine 'Scrub' solutions ... surfactants. Each is effective ...
Triad Plus PVP-I Scrub Solution has broad-spectrum germicidal action.This special formula is designed to help break down body oils and yet limit the bubbles the surfactants allowing easy removal and ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... are designed for individual application and are ... in nursing homes, home healthcare settings, blood ... hospital departments. This unit dose pouch contains ... germicidal and cleansing agent. Hydrogen Peroxide's chief ...
Medicine Products: